Prevalence of metabolic obesity in patients with Barrett's Oesophagus and its potential role in carcinogenesis

Not Applicable

Completed

• Conditions: Barrett's Oesophagus and metabolic obesity; Digestive System; Barrett's Oesophagus

• Registration Number: ISRCTN99001055
• Lead Sponsor: niversity College London Hospital [UCLH] (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01-05
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 460

Inclusion Criteria

1. Able to understand the nature and requirements of the study and to provide written informed consent
2. Aged 18 - 79 years
3. Booked to undergo routine oesophagogastroduodenoscopy

Exclusion Criteria

1. Weight loss of more than 10% in the last year
2. Known decompensated liver disease
3. Coeliac disease
4. Inflammatory bowel disease
5. Previous upper gastrointestinal tract surgery
6. Known malignancy or undergoing treatment for previously resected malignancy
7. Inability to provide informed consent

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of overweight, obesity, and metabolic obesity in subjects with Barrett's Oesophagus as compared to subjects without Barrett's Oesophagus (standardised for age and sex).<br><br>All the measures will be done only once at baseline, when patients attend their endoscopy test as part of their clinical management.<br><br>No follow-up is required.

Secondary Outcome Measures

Name	Time	Method
1. The characteristics of body composition, metabolic parameters and serum level of adiponectin/leptin in obese, overweight and metabolic obese subjects compared to those of normal weight.<br>2. The prevalence of abdominal obesity (in obese and overweight subjects) and metabolic obesity in subjects with dysplastic Barrett's oesophagus compared to those without dysplasia.<br><br>All the measures will be done only once at baseline, when patients attend their endoscopy test as part of their clinical management. No follow-up is required.